Review Article

Medication-Related Osteonecrosis of the Jaw: A Reflection of Current Preventative and Therapeutic Guidelines: A Review

Hassan Dib
Lebanese University, Lebanon
* Corresponding author
Wael Khalil
Lebanese University, Lebanon
Houssam Jassar
Lebanese University, Lebanon
Mohamad Houmnani
Lebanese University, Lebanon
DOI icon 10.24018/ejdent.2022.3.2.57

Read Counter
185

Downloads
165

Citations

Share

Article Sidebar

Submitted 2022-02-11
Published 2022-03-11

Read counter = 185 times

Table of Contents

Article Main Content

Medication-related osteonecrosis of the jaw (MRONJ) is a serious side effect of bisphosphonates, denosumab, and antiangiogenic drugs. Although the literature is rich with research work discussing MRONJ, the pathogenesis of this devastating condition has not been adequately understood yet. Roles of infection, immunity and genetic predisposition have been extremely unclear. Moreover, many controversies have been governing risk assessment and management guidelines. In 2003, 36 cases of osteonecrosis of the jaw (ONJ) associated with the use of either pamidronate or zoledronate were reported. Furthermore, in 2014, the American Association of Oral and Maxillofacial Surgeons (AAOMS) suggested the term “medication-related osteonecrosis of the jaw” (MRONJ) to describe jaw osteonecrosis related to the use of medications. This review sheds the light on recent research work discussing the pathogenesis of MRONJ. Moreover, it suggests possible guidelines for risk assessment and management based on information gathered from different research papers found in the literature.

Keywords: Bisphosphonate, MRONJ, pathogenesis, risk factors

References

  1. Capocci M, Romeo U, Guerra F. Medication-related osteonecrosis of the jaws (MRONJ) and quality of life evaluation: a pilot study. La Clinica Terapeutica. 2017: 253–257.
     Google Scholar
  2. Khan AA, Morrison A, Hanley DA, Felsenberg D, MacCauley LM, O'Ryan F, et al. Diagnosis and Management of Osteonecrosis of the Jaw: A Systematic Review and International Consensus: osteonecrosis of the jaw: report from the international onj task force. J Bone Miner Res. 2015; 30: 3–23.
     Google Scholar
  3. Tu KN, Lie JD, Wan CKV, Cameron M, Austel AG, Nguyen JK, et al. Osteoporosis: A Review of Treatment Options. P T. 2018; 43: 92–104.
     Google Scholar
  4. Lipton A, Uzzo R, Amato RJ, Ellis GK, Hakimian B, Roodman GD, et al. The Science and Practice of Bone Health in Oncology: Managing Bone Loss and Metastasis in Patients With Solid Tumors. J Natl Compr Canc Netw. 2009; 7: S-1-S-29.
     Google Scholar
  5. Beth-Tasdogan NH, Mayer B, Hussein H, Zolk O. Interventions for managing medication-related osteonecrosis of the jaw. Cochrane Database of Systematic Reviews. 2017.
     Google Scholar
  6. Pimolbutr K, Porter S, Fedele S. Osteonecrosis of the Jaw Associated with Antiangiogenics in Antiresorptive-Naïve Patient: A Comprehensive Review of the Literature. BioMed Research International. 2018; 2018: 1–14.
     Google Scholar
  7. Khan AA, Morrison A, Kendler DL, Rizzoli R, Hanley DA, Felsenberg D, et al. Case-Based Review of Osteonecrosis of the Jaw (ONJ) and Application of the International Recommendations for Management From the International Task Force on ONJ. Journal of Clinical Densitometry. 2017; 20: 8–24.
     Google Scholar
  8. Bolette A, Lecloux G, Rompen E, Albert A, Kerckhofs G, Lambert F. Influence of induced infection in medication-related osteonecrosis of the jaw development after tooth extraction: A study in rats. Journal of Cranio-Maxillofacial Surgery. 2019; 47: 349–356.
     Google Scholar
  9. Patntirapong S, Phupunporn P, Vanichtantiphong D, Thanetchaloempong W. Inhibition of macrophage viability by bound and free bisphosphonates. Acta Histochemica. 2019; 121: 400–406.
     Google Scholar
  10. Kim RH, Lee RS, Williams D, Bae S, Woo J, Lieberman M, et al. Bisphosphonates Induce Senescence in Normal Human Oral Keratinocytes. J Dent Res. 2011; 90: 810–816.
     Google Scholar
  11. Kurkjian C, Kim ES. Risks and benefits with bevacizumab: evidence and clinical implications. Therapeutic Advances in Drug Safety. 2012; 3: 59–69.
     Google Scholar
  12. Fedele S, Bedogni G, Scoletta M, Favia G, Colella G, Agrillo A, et al. Up to a quarter of patients with osteonecrosis of the jaw associated with antiresorptive agents remain undiagnosed. British Journal of Oral and Maxillofacial Surgery. 2015; 53: 13–17.
     Google Scholar
  13. Ruggiero SL, Dodson TB, Fantasia J, Goodday R, Aghaloo T, Mehrotra B, et al. American Association of Oral and Maxillofacial Surgeons Position Paper on Medication-Related Osteonecrosis of the Jaw—2014 Update. Journal of Oral and Maxillofacial Surgery. 2014; 72: 1938–1956.
     Google Scholar
  14. Ruggiero SL, Fantasia J, Carlson E. Bisphosphonate-related osteonecrosis of the jaw: background and guidelines for diagnosis, staging, and management. Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontology. 2006; 102: 433–441.
     Google Scholar
  15. Ruggiero SL, Dodson TB, Assael LA, Landesberg R, Marx RE, Mehrotra B, et al. American Association of Oral and Maxillofacial Surgeons Position Paper on Bisphosphonate-Related Osteonecrosis of the Jaw – 2009 Update. Australian Endodontic Journal. 2009; 35: 119–130.
     Google Scholar
  16. Stockmann P, Hinkmann FM, Lell MM, Fenner M, Vairaktaris E, Neukam FW, et al. Panoramic radiograph, computed tomography or magnetic resonance imaging. Which imaging technique should be preferred in bisphosphonate-associated osteonecrosis of the jaw? A prospective clinical study. Clin Oral Invest. 2010; 14: 311–317.
     Google Scholar
  17. Ogura I, Sasaki Y, Kameta A, Sue M, Oda T. Characteristic Multimodal Imaging of Medication- Related Osteonecrosis of the Jaw: Comparison Between Oral and Parenteral Routes of Medication Administration. PJR. 2017; 82: 551–560.
     Google Scholar
  18. Loyson T, Van Cann T, Schöffski P, Clement PM, Bechter O, Spriet I, et al. Incidence of osteonecrosis of the jaw in patients with bone metastases treated sequentially with bisphosphonates and denosumab. Acta Clinica Belgica. 2018; 73: 100–109.
     Google Scholar
  19. Bagan JV, Jiménez Y, Gómez D, Sirera R, Poveda R, Scully C. Collagen telopeptide (serum CTX) and its relationship with the size and number of lesions in osteonecrosis of the jaws in cancer patients on intravenous bisphosphonates. Oral Oncology. 2008; 44: 1088–1089.
     Google Scholar
  20. Hamada S. Surgical treatment with hyperbaric oxygen in the management of bisphosphonate-related osteonecrosis of the jaw. Journal of Oral and Maxillofacial Surgery. 2014; 72: e91–e92.
     Google Scholar
  21. Goodell GG. Guidelines for Medication-related Osteonecrosis of the Jaw: An update. [Internet] 2020. Available from: https://www.aae.org/specialty/communique/guidelines-for-medication-related-osteonecrosis-jaw-an-update/
     Google Scholar
  22. Lodi G, Sardella A, Salis A, Demarosi F, Tarozzi M, Carrassi A. Tooth Extraction in Patients Taking Intravenous Bisphosphonates: A Preventive Protocol and Case Series. Journal of Oral and Maxillofacial Surgery. 2010; 68: 107–110.
     Google Scholar
  23. Nicolatou-Galitis O, Schiødt M, Mendes RA, Ripamonti C, Hope S, Drudge-Coates L, et al. Medication-related osteonecrosis of the jaw: definition and best practice for prevention, diagnosis, and treatment. Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology. 2019; 127: 117–135.
     Google Scholar